HeartBeam, a medical technology company focused on advancing cardiac care, announced the appointment of Bryan Humbarger as chief commercial officer, effective January 22, 2026. In this newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives for the company's cardiac technology platform.
The appointment comes at a critical juncture for HeartBeam as it prepares for the limited launch of its recently cleared HeartBeam System. This system includes technology for arrhythmia assessment and heart attack detection, along with a 12-lead ECG extended wear patch monitor. Humbarger's responsibilities will include expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption of the technology.
HeartBeam's technology represents a significant advancement in cardiac care. The company is creating the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, delivering what the company describes as "actionable heart intelligence."
The clinical implications of this technology are substantial. Physicians will potentially be able to identify cardiac health trends and acute conditions while directing patients to appropriate care—all outside of traditional medical facilities. This capability could redefine the future of cardiac health management by enabling earlier detection and intervention for critical cardiac events.
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. According to the company's cleared indications for use available at https://www.heartbeam.com/indications, the technology has specific medical applications that have undergone regulatory review. The company's 3D ECG technology had previously received FDA clearance for arrhythmia assessment in December 2024, establishing a regulatory pathway for its broader cardiac monitoring platform.
Humbarger's appointment signals HeartBeam's transition from technology development to commercial implementation. His role will focus on executing the company's growth initiatives during a period when remote cardiac monitoring technologies are gaining increased attention from healthcare providers and patients alike. The commercial strategy will likely address how this technology integrates into existing cardiac care pathways while demonstrating clinical and economic value to healthcare systems.
The broader context for this development includes increasing demand for remote patient monitoring solutions and technologies that can detect cardiac events before they become emergencies. HeartBeam's approach to creating a portable, cable-free system that generates clinical-grade 12-lead ECGs could address significant gaps in current cardiac care, particularly for patients who experience symptoms outside clinical settings. The company's news and updates relating to its NASDAQ-listed stock BEAT are available in its newsroom at https://ibn.fm/BEAT.
As with many medical technology companies, HeartBeam's forward-looking statements involve risks and uncertainties that may affect actual results. These statements are subject to factors beyond management's control, including those detailed in the company's SEC filings. The full terms of use and disclaimers applicable to content provided by the InvestorBrandNetwork are available at http://IBN.fm/Disclaimer.
